ReviewFrontiers in oncology2022

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?

Alec S Britt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.